Trials / Completed
CompletedNCT04352335
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator
Change in Neutrophil to Lymphocyte Ratio (NLR) and Survival Among Advanced Lung Cancer Patients Receiving Immune Checkpoint Inhibitors With Immunomodulator: a Retrospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 53 (actual)
- Sponsor
- Chung Shan Medical University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.
Detailed description
In recent years, the therapeutic strategies for lung cancer have been enriched with small molecular targeted therapy and immunotherapy. In this retrospective study, we will observe the change in NLR and explore its possible association with survival among advanced lung cancer patients receiving Immune checkpoint inhibitors (ICIs) with and without such immuno-modulator, Astragalus Polysaccharide Injection. It can be used to understand the relationship between NLR values and the survival rate of lung cancer patients after ICIs treatment. Physicians can refer to this result to give patients the suitable treatment recommendations.
Conditions
Timeline
- Start date
- 2020-04-14
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
- First posted
- 2020-04-20
- Last updated
- 2020-07-02
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04352335. Inclusion in this directory is not an endorsement.